Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Revenue (2016 - 2024)

Historic Revenue for Avalo Therapeutics (AVTX) over the last 10 years, with Q4 2024 value amounting to $192000.0.

  • Avalo Therapeutics' Revenue fell 6637.48% to $192000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $192000.0, marking a year-over-year decrease of 7658.54%. This contributed to the annual value of $441000.0 for FY2024, which is 7707.9% down from last year.
  • Latest data reveals that Avalo Therapeutics reported Revenue of $192000.0 as of Q4 2024, which was down 6637.48% from $249000.0 recorded in Q3 2024.
  • In the past 5 years, Avalo Therapeutics' Revenue registered a high of $14.9 million during Q3 2022, and its lowest value of $192000.0 during Q4 2024.
  • Moreover, its 5-year median value for Revenue was $964500.0 (2022), whereas its average is $1.8 million.
  • As far as peak fluctuations go, Avalo Therapeutics' Revenue soared by 100733.33% in 2022, and later tumbled by 9842.13% in 2023.
  • Over the past 5 years, Avalo Therapeutics' Revenue (Quarter) stood at $1.5 million in 2020, then crashed by 85.37% to $219000.0 in 2021, then soared by 309.13% to $896000.0 in 2022, then plummeted by 36.27% to $571000.0 in 2023, then tumbled by 66.37% to $192000.0 in 2024.
  • Its Revenue was $192000.0 in Q4 2024, compared to $249000.0 in Q3 2024 and $571000.0 in Q4 2023.